A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Issue 3 (9th March 2021)

• Record Type: Journal Article
• Authors: Li, Chunrui; Cao, Wenyue; Que, Yimei; Wang, Qiuxiang; Xiao, Yi; Gu, Chaojiang; Wang, Di; Wang, Jue; Jiang, Lijun; Xu, Hao; Xu, Jinhuan; Zhou, Xiaoxi; Hong, Zhenya; Wang, Na; Huang, Liang; Zhang, Shangkun; Chen, Liting; Mao, Xia; Xiao, Min; Zhang, Wei; Meng, Li; Cao, Yang; Zhang, Tongcun; Li, Jian; Zhou, Jianfeng
• Is Part Of: Clinical and translational medicine. Volume 11:Issue 3(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-09
• Subjects: anti‐BCMA CAR T cell -- multiple myeloma -- plasma cell leukemia -- relapsed/refractory; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1002/ctm2.346
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment. This study was designed to assess the safety and preliminary efficacy of a novel anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell in R/R MM and PCL. Methods: Between February 22, 2017, and June 25, 2018, 28 R/R and two R/R primary PCL patients received a median dose of 11.2 × 10 6 CAR+ cells/kg. The subjects were refractory to a proteasome inhibitor and/or an immunomodulatory agent. Fludarabine and cyclophosphamide were given as lymphodepletion chemotherapy. Results: Results for these 30 consecutive patients who received an anti‐BCMA CAR T cell infusion are reported. The patients had received a median of four prior lines of therapy. A total of 44 different types of adverse events were recorded, and hematologic toxic effects were the most common events of any grade during treatment. Hematologic toxic effects were also the most common events of grade 3 or higher. A total of 29 patients (96.7%) had cytokine release syndrome, which was of grade 1 or 2 in 24 patients (80%) and grade 3 in five patients (16.7%). Neurologic toxic effects only occurred in one patient (3.3%) and were of grade 1. The objective response rate was 90%, and the complete response rate was 43.3%. With a median follow‐up of 12.6 months, the median progression‐free survival (PFS) and overall survival were 5.2 months and 14.0 months. One of the two primary PCL achieved a complete response with a PFS of 307 days. The other patients achieved a very good partial response with a PFS of 117 days. Conclusions: Anti‐BCMA CAR T cell treatment is safe and highly active in R/R multiple myeloma. Abstract : We report the efficacy and safety of the infusion of anti‐BCMA CAR T cell treatment in with relapsed/refractory malignant plasma cell disease. Anti‐BCMA CAR T cell therapy exerted better safety and preliminary efficacy in relapsed/refractory multiple myeloma. Relapsed/refractory primary plasma cell leukemia may benefit from CAR T Cell treatment, although the duration of response is short.